Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA6 | P23280 | 5/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA4 | P22748 | 4/20 | 0.57 |
| ▸ | CA5A | P35218 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | CASP2 | P42575 | 2/20 | 0.57 |
| ▸ | F13A1 | P00488 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | THPO | P40225 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977637 | 0.95 | — | — | |
| SCHEMBL28877991 | 0.87 | — | — | |
| SCHEMBL7871253 | 0.85 | CA12 (0.55) | CA12CA6CA7CA9CA14 | |
| SCHEMBL11289976 | 0.84 | CA12 (0.61) | CA12CA6CA7CA9CA14 | |
| SCHEMBL456181 | 0.84 | — | — | |
| SCHEMBL28988583 | 0.81 | — | — | |
| Thermine SCHEMBL181589 | 0.81 | CA12 (0.86) | CA12CA6CA7CA9CA14 | |
| SCHEMBL869672 | 0.81 | CA12 (0.86) | CA12CA6CA7CA9CA14 | |
| SCHEMBL870789 | 0.81 | CA12 (0.86) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3159043 | 0.81 | CA12 (0.86) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | CA12 2088/4885CA6 2334/4885CA7 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.